-
Innovation Ranking
NewInnovation Ranking – Alpine Immune Sciences Inc
Alpine Immune Sciences Inc (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company. The company focuses on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The company also provides ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer. It offers a proprietary scientific platform that converts native immune...
-
Product Insights
NewLikelihood of Approval Analysis for Primary Immune Deficiency (PID)
Overview How likely is it that the drugs in Primary Immune Deficiency (PID) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Primary Immune Deficiency (PID) Overview Primary immune deficiency (PID) is...
-
Product Insights
NewLikelihood of Approval Analysis for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Overview How likely is it that the drugs in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview Idiopathic...
-
Product Insights
NewNet Present Value Model: Immunic Inc’s Vidofludimus calcium
Empower your strategies with our Net Present Value Model: Immunic Inc's Vidofludimus calcium report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Epilepsy Drug Details: Human immunoglobulin (Privigen /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Tachycardia (Tachyarrhythmias)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Tachycardia (Tachyarrhythmias) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Tachycardia (Tachyarrhythmias) Drug Details: Human Immunoglobulin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-881 in Primary Immune Deficiency (PID)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-881 in Primary Immune Deficiency (PID) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-881 in Primary Immune Deficiency (PID) Drug Details: TAK-881 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CABA-201 in Immune Mediated Necrotizing Myopathy (IMNM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CABA-201 in Immune Mediated Necrotizing Myopathy (IMNM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CABA-201 in Immune Mediated Necrotizing Myopathy (IMNM) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human))...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Immune Mediated Necrotizing Myopathy (IMNM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Immune Mediated Necrotizing Myopathy (IMNM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Immune Mediated Necrotizing Myopathy (IMNM)...